The stock has a 36-month beta value of 0.04. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for INAB is 57.73M, and at present, short sellers hold a 0.84% of that float. On January 17, 2025, the average trading volume of INAB was 1.39M shares.
INAB) stock’s latest price update
The stock of IN8bio Inc (NASDAQ: INAB) has decreased by -1.01 when compared to last closing price of 0.30. Despite this, the company has experienced a -9.19% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-10 that IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
INAB’s Market Performance
INAB’s stock has fallen by -9.19% in the past week, with a monthly rise of 4.26% and a quarterly rise of 28.27%. The volatility ratio for the week is 13.85% while the volatility levels for the last 30 days are 13.68% for IN8bio Inc The simple moving average for the past 20 days is 2.84% for INAB’s stock, with a -53.38% simple moving average for the past 200 days.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with Laidlaw repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to Laidlaw is $7.50 based on the research report published on March 18, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see INAB reach a price target of $14. The rating they have provided for INAB stocks is “Buy” according to the report published on August 30th, 2022.
INAB Trading at -3.95% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.13% of loss for the given period.
Volatility was left at 13.68%, however, over the last 30 days, the volatility rate increased by 13.85%, as shares surge +1.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.23% lower at present.
During the last 5 trading sessions, INAB fell by -9.74%, which changed the moving average for the period of 200-days by -73.47% in comparison to the 20-day moving average, which settled at $0.2854. In addition, IN8bio Inc saw 14.15% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for INAB
Current profitability levels for the company are sitting at:
- -8.5 for the present operating margin
- 0.5 for the gross margin
The net margin for IN8bio Inc stands at -8.5. The total capital return value is set at -2.58. Equity return is now at value -241.97, with -151.16 for asset returns.
Based on IN8bio Inc (INAB), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -4.56. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is -54.03.
Currently, EBITDA for the company is -28.5 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 6.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
To sum up, IN8bio Inc (INAB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
